Prognostic analysis of patients with gastrointestinal stromal tumors: A single unit experience with surgical treatment of primary disease

Chinese Medical Journal

Volumn 123, Issue 2, 2010, Pages 131-136

  Cao, Hui ^a   Zhang, Yun ^a   Wang, Ming ^a   Shen, Dan Ping ^a   Sheng, Zhi Yong ^a   Ni, Xing Zhi ^a   Wu, Zhi Yong ^a   Liu, Qiang ^a   Shen, Yan Ying ^a   Song, Yan Yan ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Gastrointestinal stromal tumors; Prognosis; Surgical resection; Targeted therapy

Indexed keywords

CD34 ANTIGEN; IMATINIB; STEM CELL FACTOR RECEPTOR;

ABDOMINAL DISTENSION; ABDOMINAL MASS; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; COLON TUMOR; DYSPHAGIA; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TUMOR; GENDER; GROUPS BY AGE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE OBSTRUCTION; MAJOR CLINICAL STUDY; MALE; MESENTERY TUMOR; METASTASIS; MITOSIS INDEX; OMENTUM; OVERALL SURVIVAL; PATIENT CODING; PERITONITIS; PROGNOSIS; RECTUM TUMOR; RETROSPECTIVE STUDY; RISK ASSESSMENT; SMALL INTESTINE TUMOR; STOMACH TUMOR; SURVIVAL RATE; SURVIVAL TIME; TUMOR CLASSIFICATION; TUMOR LOCALIZATION; TUMOR RECURRENCE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 76549089243     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.02.001     Document Type: Article

References (22)

1. Tornillo L, Terracciano LM. An update on molecular genetics of gastrointestinal stromal tumors. J Clin Pathol 2006; 59: 557-556.
2. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-58.
3. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33: 459-465.
4. Kamiyama Y, Aihara R, Nakabayashi T, Mochiki E, Asao T, Kuwano H, et al. 18F-Fluorodeoxyglucose position emission tomography: Useful technique for predicting maligant potential of gastrointestinal stromal tumors. Wold J Surg 2005; 29: 1492-1495.
5. Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26: 620-625.
6. Nilsson B, Bümming P, Meis-Kindblom JM, Odén A, Dortok A, Gustavsson B, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era - a population-based study in western Sweden. Cancer 2005; 103: 821-829.
7. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach. A clinicopathologic, immunohisto-chemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005; 29: 52-68.
8. Miettinen M, Makhlouf H, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum. A clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 2006; 30: 477-489.
9. Zhang XH, He YL, Zhan WH, Cai SR, Zhang CH. Diagnosis and treatment of gastrointestinal stromal tumors: report of 135 cases. Chin J Gastrointestinal Surg (Chin) 2007; 10: 17-20.
10. Trent JC, Benjamin RS. New developments in gastrointestinal stromal tumors. Curr Opin Oncol 2006; 18: 386-395.
11. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, et al. PDGFA activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708.
12. Ahmed I, Welch NT, Parsons SL. Gastrointestinal stromal tumours (GIST) - 17 years experience from Mid Trent Region (United Kingdom). Eur J Surg Oncol 2008; 34: 445-449.
13. Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST) - update of the NCCN clinical practice guidelines. J Natl Compr Care Netw 2007; 5 Suppl 2: S1-29.
14. Tryggvason G, Kristmundsson T, Orvar K, Jónasson JG, Magnússon MK, Gíslason HG. Clinical study on gastrointestinal stromal tumors (GIST) in Iceland, 1990-2003. Dig Dis Sci 2007; 52: 2249-2253.
15. Gold JS, Dematteo RP. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg 2006; 244: 176-184.
16. Clary BM, DeMatteo RP, Lewis JJ, Leung D, Brennan MF. Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperitoneum: a clinical comparison. Ann Surg Oncol 2001; 8: 290-299.
17. An JY, Choi MG, Noh JH, Sohn TS, Kang WK, Park CK, et al. Gastric GIST: a single institutional retrospective experience with surgical treatment for primary disease. Eur J Surg Oncol 2007; 33: 1030-1035.
18. Rossi CR, Mocellin S, Mencarelli R, Foletto M, Pilati P, Nitti D, et al. Gastrointestinal strormal tumours from surgical to a molecular approach. Int J Cancer 2003; 107: 171-176.
19. Verweij J, van Oosterom A, Blay JY, Judson I, Rodenhuis S, van der Graaf W, et al. Imatinib mesylate (STI-571 Glivec(R), Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003; 39: 2006-2011.
20. Sawaki A, Yamao K, Nakamura T, Suzuki T, Okubo K, Hara K, et al. A pilot study of imatinib mesylate (STI571) on gastrointestinal stromal tumors in Japanese patients. J Gastroenterol 2004; 39: 329-333.
21. Zhan WH, Wang PZ, Shao YF, Wu XT, Gu J, Li R, et al. Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial. Chin J Gastrointest Surg (Chin) 2006; 9: 383-387.
22. Blay JY, Le Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French sarcoma group. J Clin Oncol 2007; 25: 1107-1113.